<DOC>
	<DOCNO>NCT01457885</DOCNO>
	<brief_summary>Although transplant result AML complete remission ( CR ) time transplant improve , transplant result non-remission AML quite poor . Most multi-center study focus standard risk AML patient many study do population patient non-remission AML . There large number old patient non-remission AML complete remission rate induction chemotherapy decrease age . Such old patient tolerate conventional full intensity conditioning regimen . Thus , effective tolerable condition regimen non-remission AML great unmet need current transplant practice . From investigator earlier study , suggest replace Fludarabine standard FluBu4 regimen Clofarabine ( relate drug much potent anti-leukemia effect ) transplant condition regimen may potentiate anti-tumor activity condition regimen without add significant toxicity , goal new condition regimen development . The investigator expect enroll total 75 patient fifteen site . The investigator main objective confirm safety efficacy measure one-year overall survival , CloBu4 combination full intensity condition non-remission acute myelogenous leukemia .</brief_summary>
	<brief_title>Multi-center Study Myeloablative Allo Stem Cell Transplant Non-remission AML Using CloBu4 Regimen</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Disease Criteria AML remission time transplant `` Not remission '' define `` great 5.0 % bone marrow blast aspirate morphology , '' determine bone marrow aspirate obtain within 2 week study registration . For primary induction failure patient : Patients must fail least 2 induction regimen . For patient relapsed disease : Patients relapse 6 month precede remission must fail least one reinduction regimen eligible . For patient precede remission equal shorter 6 month duration , reinduction regimen require qualify protocol . If pretransplant bone marrow aspirate biopsy hypoplastic ( less 10 % cellularity ) , blast percentage determine , patient eligible precede bone marrow meet criterion . Patients peripheral circulate blast patient extramedullary leukemia eligible bone marrow aspirate biopsy meet criteria . Age Organ Function Criteria Age : 2 65 year age . Cardiac : LVEF ≥ 40 % MUGA ( Multi Gated Acquisition ) scan echocardiogram . Pulmonary : FEV1 FVC capacity ) ≥ 40 % predict , DLCO ( correct hemoglobin ) ≥ 40 % predict . Children unable cooperate pulmonary function test ( PFTs ) , must evidence dyspnea rest , exercise intolerance , require supplemental oxygen therapy . Renal : Age equal old 12 : The estimated creatinine clearance ( CrCl ) must equal great 60 mL/min/1.73 m2 calculate CockcroftGault Formula . Age young 12 : Either estimate measure CrCl great 90 ml/min/1.73m2 . For estimation , Schwartz formula use . Hepatic : Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; ( AST ) / ALT ≤ 2.5 x ULN ; Alkaline phosphatase ≤ 2.5 x ULN Performance status : Karnofsky ≥ 70 % . , Lansky≥70 % Consent : All patient must sign informed consent Active lifethreatening cancer require treatment AML Noncompliant medication . No appropriate caregiver identify . HIV1 ( Human Immunodeficiency Virus1 ) HIV2 positive Active lifethreatening cancer require treatment AML Uncontrolled medical psychiatric disorder . Uncontrolled infection , define positive blood culture within 72 hour study entry , evidence progressive infection Active central nervous system ( CNS ) leukemia Preceding allogeneic HSCT Receiving intensive chemotherapy within 21 day registration . Patients precede primary myelofibrosis Peripheral blast &gt; 10,000/μL time registration</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
</DOC>